Wide Ranks

MRNA

Moderna, Inc.

43.39

Top Statistics
Market Cap 16 B Forward PE -4.90 Revenue Growth 1.70 %
Current Ratio 4.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -43.77 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.74 Enterprise / Revenue 2.20 Price To Sales Trailing12 Months 3.29
Profitability
Profit Margins -43.77 % Operating Margins -3.76 %
Balance Sheet
Total Cash 6 B Total Cash Per Share 17.84 Total Debt 1 B
Total Debt To Equity 11.36 Current Ratio 4.39 Book Value Per Share 30.98
All Measures
Short Ratio 512.00 % Message Board Id finmb_128680956 Fax 617 649 3910
Shares Short Prior Month 33 M Return On Equity -0.1752 City Cambridge
Uuid 210c0d72-66a5-36d2-944f-611b6274a1fc Previous Close 42.05 First Trade Date Epoch Utc 1 B
Book Value 30.98 Beta 1.69 Total Debt 1 B
Volume 5 M Price To Book 1.40 Fifty Two Week Low 35.80
Total Cash Per Share 17.84 Total Revenue 5 B Shares Short Previous Month Date 1 B
Target Median Price 61.00 Max Age 86400 Recommendation Mean 2.59
Sand P52 Week Change 0.3133 Operating Margins -3.76 % Target Mean Price 76.36
Net Income To Common -2224000000 Short Percent Of Float 0.1363 Implied Shares Outstanding 384 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 11 M
Average Volume10days 11 M Total Cash 6 B Next Fiscal Year End 1 B
Revenue Per Share 13.28 Held Percent Insiders 0.0952 Ebitda Margins -46.49 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 42.05 Target Low Price 31.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 53.32 Open 42.56 Free Cashflow -3337125120
State MA Dividend Yield 0.00 % Return On Assets -0.0955
Time Zone Short Name EST Trailing Eps -5.81 Day Low 42.08
Address1 200 Technology Square Shares Outstanding 384 M Price Hint 2
Target High Price 212.00 Website https://www.modernatx.com 52 Week Change -0.4416
Average Volume 6 M Forward Eps -8.70 Recommendation Key hold
Compensation As Of Epoch Date 1 B Quick Ratio 395.40 % Is_sp_500 True
Regular Market Day High 43.46 Profit Margins -43.77 % Debt To Equity 11.36
Fifty Two Week High 170.47 Day High 43.46 Shares Short 39 M
Regular Market Open 42.56 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2.20 Revenue Growth 1.70 % Shares Percent Shares Out 0.1036
Operating Cashflow -3207000064 Currency USD Time Zone Full Name America/New_York
Market Cap 16 B Is_nasdaq_100 False Zip 02139
Quote Type EQUITY Industry Biotechnology Long Name Moderna, Inc.
Regular Market Day Low 42.08 Held Percent Institutions 0.7160 Current Price 43.39
Enterprise To Ebitda -4.74 Financial Currency USD Current Ratio 4.39
Gross Margins -27.55 % Industry Disp Biotechnology Number Of Analyst Opinions 22
Country United States Float Shares 347 M Two Hundred Day Average 95.44
Enterprise Value 11 B Price To Sales Trailing12 Months 3.29 Forward PE -4.90
Regular Market Volume 5 M Ebitda -2361999872 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.

Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.

It has strategic alliances and collaborations with AstraZeneca; Merck & Co.

, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.

p.

A.

; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.

The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.